Effectiveness and tolerability of switching to aripiprazole from risperidone in subjects with autism spectrum disorders: A prospective open-label study

Clinical Neuropharmacology

Volumn 36, Issue 5, 2013, Pages 151-156

  Ishitobi, Makoto ^a,b   Kosaka, Hirotaka ^a   Takahashi, Tetsuya ^a   Yatuga, Chiho ^a   Asano, Mizuki ^a   Tanaka, Yuji ^a   Ueno, Kanji ^a   Okazaki, Ryoko ^a   Omori, Masao ^c   Hiratani, Michio ^b   Tomoda, Akemi ^a   Wada, Yuji ^a  

^a UNIVERSITY OF FUKUI   (Japan)

^b Hiratani Child Development Clinic   (Japan)

^c FUKUI PREFECTURAL UNIVERSITY   (Japan)

Author keywords

aripiprazole; autism spectrum disorders (ASDs); risperidone; switching; tolerability issues

Indexed keywords

ARIPIPRAZOLE; ATOMOXETINE; CARBAMAZEPINE; METHYLPHENIDATE; PROLACTIN; RAMELTEON; RISPERIDONE; VALPROIC ACID;

ADOLESCENT; ADULT; ARTICLE; ASPERGER SYNDROME; AUTISM; CHILD; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; HUMAN; HYPERPROLACTINEMIA; INCREASED APPETITE; MAINTENANCE DRUG DOSE; MALE; OPEN STUDY; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROSPECTIVE STUDY; SCHOOL CHILD; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; WEIGHT GAIN;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; CHILD; CHILD DEVELOPMENT DISORDERS, PERVASIVE; DRUG ADMINISTRATION SCHEDULE; HUMANS; MALE; PIPERAZINES; PROLACTIN; PSYCHIATRIC STATUS RATING SCALES; QUINOLONES; RISPERIDONE; YOUNG ADULT;

EID: 84885067457     PISSN: 03625664     EISSN: 1537162X     Source Type: Journal    
DOI: 10.1097/WNF.0b013e3182a31ec0     Document Type: Article

References (35)

1. Myers SM. The status of pharmacotherapy for autism spectrum disorders. Expert Opin Pharmacother 2007;8:1579-1603.
2. Leskovec TJ, Rowles BM, Findling RL. Pharmacological treatment options for autism spectrum disorders in children and adolescents. Harv Rev Psychiatry 2008;16:97-112.
3. West L, Waldrop J, Brunssen S. Pharmacologic treatment for the core deficits and associated symptoms of autism in children. J Pediatr Health Care 2009;23:75-89.
4. Matson JL, Hess JA. Psychotropic drug efficacy and side effects for persons with autism spectrum disorders. Res Autism Spectr Disord 2011;5:230-236.
5. Matson JL, Sipes M, Fodstad JC, et al. Issues in the management of challenging behaviours of adults with autism spectrum disorder. CNS Drugs 2011;25:597-606.
6. Gukan CK, Hagerman RJ. Targeted treatments in autism and fragile X syndrome. Res Autism Spectr Disord 2012;6:1311-1320.
7. Canitano R, Scandurra V. Psychopharmacology in autism: an update. Prog Neuropsychopharmacol Biol Psychiatry 2011;35:18-28.
8. McPheeters ML, Warren Z, Sathe N, et al. A systematic review of medical treatments for children with autism spectrum disorders. Pediatrics 2011;127:e1312-e1321.
9. Lemmon ME, Gregas M, Jeste SS. Risperidone use in autism spectrum disorders: a retrospective review of a clinic-referred patient population. J Child Neurol 2010;26:428-432.
10. Levy SE, Hyman SL. Novel treatments for autistic spectrum disorders. Ment Retard Dev Disabil Res Rev 2005;11:131-142.
11. McDougle CJ, Scahill L, McCracken JT, et al. Risperidone for the core symptom domains of autism: results from the study by the autism network of the research units on pediatric psychopharmacology. Am J Psychiatry 2005;162:1142-1148.
12. Barnard L, Young AH, Pearson J, et al. A systematic review of the use of atypical antipsychotics in autism. J Psychopharmacol 2002;16:93-101.
13. Canitano R, Scandurra V. Risperidone in the treatment of behavioral disorders associated with autism in children and adolescents. Neuropsychiatr Dis Treat 2008;4:723-730.
14. Jordan S, Koprivica V, Chen R, et al. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacol 2002;441:137-140.
15. Hirose T, Uwahodo Y, Yamada S, et al. Mechanism of action of aripiprazole predicts clinical efficacy and a favourable side-effect profile. J Psychopharmacol 2004;18:375-383.
16. Marcus RN, Owen R, Kamen L, et al. A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. J Am Acad Child Adolesc Psychiatry 2009;48:1110-1119.
17. Owen R, Sikich L, Marcus RN, et al. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics 2009;124:1533-1540.
18. Casey DE, Carson WH, Saha AR, et al. Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study. Psychopharmacology (Berl) 2003;166:391-399.
19. Naber D, Lambert M. Aripiprazole: a new atypical antipsychotic with a different pharmacological mechanism. Prog Neuropsychopharmacol Biol Psychiatry 2004;28:1213-1219.
20. Ishitobi M, Hiratani M, Kosaka H, et al. Switching to aripiprazole in subjects with pervasive developmental disorders showing tolerability issues with risperidone. Prog Neuropsychopharmacol Biol Psychiatry 2012;37(1):128-131.
21. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Washington, DC: American Psychiatric Press; 2000.
22. DiLalla DL, Rogers SJ. Domains of the Childhood Autism Rating Scale: relevance for diagnosis and treatment. J Autism Dev Disord 1994;24:115-128.
23. Aman MG, Singh NN, Stewart AW, et al. The Aberrant Behavior Checklist: a behavior rating scale for the assessment of treatment effects. Am J Ment Defic 1985;89:485-491.
24. Brown EC, Aman MG, Havercamp SM. Factor analysis and norms for parent ratings on the Aberrant Behavior Checklist-Community for young people in special education. Res Dev Disabil 2002;23:45-60.
25. Masi G, Cosenza A, Mucci M, et al. A 3-year naturalistic study of 53 preschool children with pervasive developmental disorders treated with risperidone. J Clin Psychiatry 2003;64:1039-1047.
26. Zuddas A, Di Martino A, Muglia P, et al. Long-term risperidone for pervasive developmental disorder: efficacy, tolerability, and discontinuation. J Child Adolesc Psychopharmacol 2000;10:79-90.
27. Nicolson R, Awad G, Sloman L. An open trial of risperidone in young autistic children. J Am Acad Child Adolesc Psychiatry 1998;37:372-376.
28. Masi G, Cosenza A, Millepiedi S, et al. Aripiprazole monotherapy in children and young adolescents with pervasive developmental disorders: a retrospective study. CNS Drugs 2009;23:511-521.
29. Marcus RN, Owen R, Manos G, et al. Aripiprazole in the treatment of irritability in pediatric patients (aged 6-17 years) with autistic disorder: results from a 52-week, open-label study. J Child Adolesc Psychopharmacol 2011;21:229-236.
30. Masand PS. A review of pharmacologic strategies for switching to atypical antipsychotics. Prim Care Companion J Clin Psychiatry 2005;7:121-129.
31. Rugino TA, Janvier YM. Aripiprazole in children and adolescents: clinical experience. J Child Neurol 2005;20:603-610.
32. Findling RL, Kauffman RE, Sallee FR, et al. Tolerability and pharmacokinetics of aripiprazole in children and adolescents with psychiatric disorders: an open-label, dose-escalation study. J Clin Psychopharmacol 2008;28:441-446.
33. Chen CH, Huang MC, Lu ML. Aripiprazole resolves symptomatic hyperprolactinemia in a male schizophrenic patient. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:893-894.
34. Roke Y, Buitelaar JK, Boot AM, et al. Risk of hyperprolactinemia and sexual side effects in males 10-20 years old diagnosed with autism spectrum disorders or disruptive behavior disorder and treated with risperidone. J Child Adolesc Psychopharmacol 2012;22:432-439.
35. Lord C, Rutter M, Le Couteur A. Autism Diagnostic Interview-Revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. J Autism Dev Disord 1994;24:659-685.